Literature DB >> 28119368

Gleason Score 7 Prostate Cancers Emerge through Branched Evolution of Clonal Gleason Pattern 3 and 4.

Adam G Sowalsky1,2, Haydn T Kissick3,4, Sean J Gerrin5, Rachel J Schaefer2, Zheng Xia6, Joshua W Russo2, M Simo Arredouani3, Glenn J Bubley2, Martin G Sanda3,4, Wei Li6, Huihui Ye7, Steven P Balk8.   

Abstract

Purpose: The molecular features that account for the distinct histology and aggressive biological behavior of Gleason pattern 4 (Gp4) versus Gp3 prostate cancer, and whether Gp3 tumors progress directly to Gp4, remain to be established.Experimental Design: Whole-exome sequencing and transcriptome profiling of laser capture-microdissected adjacent Gp3 and cribiform Gp4 were used to determine the relationship between these entities.
Results: Sequencing confirmed that adjacent Gp3 and Gp4 were clonal based on multiple shared genomic alterations. However, large numbers of unique mutations in the Gp3 and Gp4 tumors showed that the Gp4 were not derived directly from the Gp3. Remarkably, the Gp3 tumors retain their indolent-appearing morphology despite acquisition of multiple genomic alterations, including tumor suppressor losses. Although there were no consistent genomic alterations that distinguished Gp3 from Gp4, pairwise transcriptome analyses identified increased c-Myc and decreased p53 activity in Gp4 versus adjacent clonal Gp3 foci.Conclusions: These findings establish that at least a subset of Gp3 and aggressive Gp4 tumors have a common origin, and support a branched evolution model wherein the Gp3 and Gp4 tumors emerge early from a common precursor and subsequently undergo substantial divergence. Genomic alterations detectable in the Gp3 may distinguish these tumors from truly indolent Gp3. Screening for a panel of these genomic alterations in men who have prostate biopsies showing only Gp3 (Gleason score 6, Gs6) may allow for more precise selection of men who can be safely managed by active surveillance versus those who may benefit from further intervention. Clin Cancer Res; 23(14); 3823-33. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28119368      PMCID: PMC5511561          DOI: 10.1158/1078-0432.CCR-16-2414

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  53 in total

1.  Recurrent copy number alterations in prostate cancer: an in silico meta-analysis of publicly available genomic data.

Authors:  Julia L Williams; Peter A Greer; Jeremy A Squire
Journal:  Cancer Genet       Date:  2014-09-16

2.  Active surveillance program for prostate cancer: an update of the Johns Hopkins experience.

Authors:  Jeffrey J Tosoian; Bruce J Trock; Patricia Landis; Zhaoyong Feng; Jonathan I Epstein; Alan W Partin; Patrick C Walsh; H Ballentine Carter
Journal:  J Clin Oncol       Date:  2011-04-04       Impact factor: 44.544

3.  Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease.

Authors:  J I Epstein; P C Walsh; H B Carter
Journal:  J Urol       Date:  2001-11       Impact factor: 7.450

4.  MYC and Prostate Cancer.

Authors:  Cheryl M Koh; Charles J Bieberich; Chi V Dang; William G Nelson; Srinivasan Yegnasubramanian; Angelo M De Marzo
Journal:  Genes Cancer       Date:  2010-06

5.  Molecular analysis of multifocal prostate cancer by comparative genomic hybridization.

Authors:  Masayuki Kobayashi; Haruna Ishida; Takayuki Shindo; Shin-Ichiro Niwa; Mika Kino; Koji Kawamura; Naoto Kamiya; Takashi Imamoto; Hiroyoshi Suzuki; Yoshifumi Hirokawa; Taizo Shiraishi; Tohru Tanizawa; Yukio Nakatani; Tomohiko Ichikawa
Journal:  Prostate       Date:  2008-12-01       Impact factor: 4.104

6.  Clonal progression of prostate cancers from Gleason grade 3 to grade 4.

Authors:  Adam G Sowalsky; Huihui Ye; Glenn J Bubley; Steven P Balk
Journal:  Cancer Res       Date:  2012-11-30       Impact factor: 12.701

7.  The genomic complexity of primary human prostate cancer.

Authors:  Michael F Berger; Michael S Lawrence; Francesca Demichelis; Yotam Drier; Kristian Cibulskis; Andrey Y Sivachenko; Andrea Sboner; Raquel Esgueva; Dorothee Pflueger; Carrie Sougnez; Robert Onofrio; Scott L Carter; Kyung Park; Lukas Habegger; Lauren Ambrogio; Timothy Fennell; Melissa Parkin; Gordon Saksena; Douglas Voet; Alex H Ramos; Trevor J Pugh; Jane Wilkinson; Sheila Fisher; Wendy Winckler; Scott Mahan; Kristin Ardlie; Jennifer Baldwin; Jonathan W Simons; Naoki Kitabayashi; Theresa Y MacDonald; Philip W Kantoff; Lynda Chin; Stacey B Gabriel; Mark B Gerstein; Todd R Golub; Matthew Meyerson; Ashutosh Tewari; Eric S Lander; Gad Getz; Mark A Rubin; Levi A Garraway
Journal:  Nature       Date:  2011-02-10       Impact factor: 49.962

8.  Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue.

Authors:  Colin S Cooper; Rosalind Eeles; David C Wedge; Peter Van Loo; Anne Y Warren; Christopher S Foster; Hayley C Whitaker; Ultan McDermott; Daniel S Brewer; David E Neal; Gunes Gundem; Ludmil B Alexandrov; Barbara Kremeyer; Adam Butler; Andrew G Lynch; Niedzica Camacho; Charlie E Massie; Jonathan Kay; Hayley J Luxton; Sandra Edwards; ZSofia Kote-Jarai; Nening Dennis; Sue Merson; Daniel Leongamornlert; Jorge Zamora; Cathy Corbishley; Sarah Thomas; Serena Nik-Zainal; Sarah O'Meara; Lucy Matthews; Jeremy Clark; Rachel Hurst; Richard Mithen; Robert G Bristow; Paul C Boutros; Michael Fraser; Susanna Cooke; Keiran Raine; David Jones; Andrew Menzies; Lucy Stebbings; Jon Hinton; Jon Teague; Stuart McLaren; Laura Mudie; Claire Hardy; Elizabeth Anderson; Olivia Joseph; Victoria Goody; Ben Robinson; Mark Maddison; Stephen Gamble; Christopher Greenman; Dan Berney; Steven Hazell; Naomi Livni; Cyril Fisher; Christopher Ogden; Pardeep Kumar; Alan Thompson; Christopher Woodhouse; David Nicol; Erik Mayer; Tim Dudderidge; Nimish C Shah; Vincent Gnanapragasam; Thierry Voet; Peter Campbell; Andrew Futreal; Douglas Easton; Michael R Stratton
Journal:  Nat Genet       Date:  2015-03-02       Impact factor: 38.330

9.  Mutations driving CLL and their evolution in progression and relapse.

Authors:  Dan A Landau; Eugen Tausch; Amaro N Taylor-Weiner; Chip Stewart; Johannes G Reiter; Jasmin Bahlo; Sandra Kluth; Ivana Bozic; Mike Lawrence; Sebastian Böttcher; Scott L Carter; Kristian Cibulskis; Daniel Mertens; Carrie L Sougnez; Mara Rosenberg; Julian M Hess; Jennifer Edelmann; Sabrina Kless; Michael Kneba; Matthias Ritgen; Anna Fink; Kirsten Fischer; Stacey Gabriel; Eric S Lander; Martin A Nowak; Hartmut Döhner; Michael Hallek; Donna Neuberg; Gad Getz; Stephan Stilgenbauer; Catherine J Wu
Journal:  Nature       Date:  2015-10-14       Impact factor: 49.962

10.  An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets.

Authors:  Karen I Zeller; Anil G Jegga; Bruce J Aronow; Kathryn A O'Donnell; Chi V Dang
Journal:  Genome Biol       Date:  2003-09-11       Impact factor: 13.583

View more
  20 in total

Review 1.  Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2019-07-30

Review 2.  Molecular correlates of intermediate- and high-risk localized prostate cancer.

Authors:  Huihui Ye; Adam G Sowalsky
Journal:  Urol Oncol       Date:  2018-03-02       Impact factor: 3.498

Review 3.  Genomic and phenotypic heterogeneity in prostate cancer.

Authors:  Michael C Haffner; Wilbert Zwart; Martine P Roudier; Lawrence D True; William G Nelson; Jonathan I Epstein; Angelo M De Marzo; Peter S Nelson; Srinivasan Yegnasubramanian
Journal:  Nat Rev Urol       Date:  2020-12-16       Impact factor: 14.432

4.  Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations.

Authors:  Adam G Sowalsky; Huihui Ye; Manoj Bhasin; Eliezer M Van Allen; Massimo Loda; Rosina T Lis; Laleh Montaser-Kouhsari; Carla Calagua; Fen Ma; Joshua W Russo; Rachel J Schaefer; Olga S Voznesensky; Zhenwei Zhang; Glenn J Bubley; Bruce Montgomery; Elahe A Mostaghel; Peter S Nelson; Mary-Ellen Taplin; Steven P Balk
Journal:  Cancer Res       Date:  2018-06-19       Impact factor: 12.701

5.  Syntaphilin Is a Novel Biphasic Biomarker of Aggressive Prostate Cancer and a Metastasis Predictor.

Authors:  Michael J Hwang; Kelly G Bryant; Jae H Seo; Qin Liu; Peter A Humphrey; Mary Ann C Melnick; Dario C Altieri; Marie E Robert
Journal:  Am J Pathol       Date:  2019-05-09       Impact factor: 4.307

6.  Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy.

Authors:  Scott Wilkinson; Huihui Ye; Fatima Karzai; Stephanie A Harmon; Nicholas T Terrigino; David J VanderWeele; John R Bright; Rayann Atway; Shana Y Trostel; Nicole V Carrabba; Nichelle C Whitlock; Stephanie M Walker; Rosina T Lis; Houssein Abdul Sater; Brian J Capaldo; Ravi A Madan; James L Gulley; Guinevere Chun; Maria J Merino; Peter A Pinto; Daniela C Salles; Harsimar B Kaur; Tamara L Lotan; David J Venzon; Peter L Choyke; Baris Turkbey; William L Dahut; Adam G Sowalsky
Journal:  Eur Urol       Date:  2021-03-27       Impact factor: 20.096

7.  Comparison of approaches to transcriptomic analysis in multi-sampled tumors.

Authors:  Anson T Ku; Scott Wilkinson; Adam G Sowalsky
Journal:  Brief Bioinform       Date:  2021-11-05       Impact factor: 13.994

Review 8.  Cancer overdiagnosis: a biological challenge and clinical dilemma.

Authors:  Sudhir Srivastava; Eugene J Koay; Alexander D Borowsky; Angelo M De Marzo; Sharmistha Ghosh; Paul D Wagner; Barnett S Kramer
Journal:  Nat Rev Cancer       Date:  2019-06       Impact factor: 60.716

9.  Serial Molecular Profiling of Low-grade Prostate Cancer to Assess Tumor Upgrading: A Longitudinal Cohort Study.

Authors:  Simpa S Salami; Jeffrey J Tosoian; Srinivas Nallandhighal; Tonye A Jones; Scott Brockman; Fuad F Elkhoury; Selena Bazzi; Komal R Plouffe; Javed Siddiqui; Chia-Jen Liu; Lakshmi P Kunju; Todd M Morgan; Shyam Natarajan; Philip S Boonstra; Lauren Sumida; Scott A Tomlins; Aaron M Udager; Anthony E Sisk; Leonard S Marks; Ganesh S Palapattu
Journal:  Eur Urol       Date:  2020-07-03       Impact factor: 20.096

Review 10.  Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance.

Authors:  Anmbreen Jamroze; Gurkamal Chatta; Dean G Tang
Journal:  Cancer Lett       Date:  2021-06-10       Impact factor: 9.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.